They also reported that compared to reference cohorts of other IDH-mutant gliomas, PMMRDIA had by far the worst clinical outcome with a median survival of only 15 months irrespective of histological or molecular features [163]. The gene discussed is IDH2; the disease is central nervous system cancer.